Role of autophagy in normal and transformed hematopoietic stem cells

描述（由申请人提供）：本申请的总体目标是了解自噬如何支持造血干细胞（HSC）的维持和功能，以及转化的HSC中这种应激反应机制的破坏如何导致髓系恶性肿瘤（如慢性髓性白血病（CML））的发展。我们最近证明造血干细胞通过诱导强大的保护性自噬反应在代谢应激中存活（Warr et al., 2013）。特别是，我们发现转录因子FoxO3A对于维持促自噬基因程序至关重要，该程序使造血干细胞能够快速诱导自噬。然而，造血干细胞如何感知代谢应激并激活自噬仍是未知的，自噬在正常和转化造血干细胞中的作用仍有待了解。我们将使用药理学和遗传学方法来剖析自噬对HSC生物学的贡献，并建立了人类慢性期CML的Scl- tTA:TRE-BCR/ABL （tTA- ba）小鼠模型（Reynaud et al., 2011）来探索自噬在白血病起始干细胞（LSC）活性和CML发展中的功能。在特异性目标1中，我们将确定造血干细胞激活自噬的机制。我们将使用我们建立的方案来诱导造血干细胞在体外和体内在细胞因子戒断和食物剥夺时的代谢应激，并将利用现有的遗传小鼠模型和化学抑制剂来确定造血干细胞如何感知代谢应激并触发自噬诱导。这些方法将确定造血干细胞如何在代谢挑战时引发保护性自噬反应。在Specific Aim 2中，我们将探讨自噬缺失如何影响体内HSC功能和基因组稳定性，并研究替代形式的蛋白质和细胞器更新是否可以支持自噬缺陷HSC的长期维持。这些方法将描述造血干细胞在体内如何正常利用自噬，以及自噬的消除如何改变正常的造血功能。在Specific Aim 3中，我们将探讨自噬在转化的表达BCR/ABL-的造血干细胞中的功能，并将利用我们的诱导型ta - ba小鼠模型来研究自噬在CML发病机制中的作用以及CML LSCs对酪氨酸激酶抑制剂（TKI）治疗的反应。这些方法将为血液系统恶性转化的机制提供重要的新见解。他们将阐明自噬在HSC转化和CML发展中的作用，并确定如何操纵自噬机制以实现治疗效益。综上所述，这些研究将揭示造血干细胞通常用于维持血液稳态的基本细胞保存机制的破坏如何导致转化的造血干细胞功能异常和血液疾病的发展。

DESCRIPTION (provided by applicant): The overall goal of this application is to understand how autophagy supports the maintenance and function of blood-forming hematopoietic stem cells (HSC), and how corruption of this stress-response mechanism in transformed HSCs contributes to the development of myeloid malignancies such as chronic myelogenous leukemia (CML). We recently demonstrated that HSCs survive metabolic stress by inducing a robust protective autophagy response (Warr et al., 2013). In particular, we showed that the transcription factor FoxO3A is essential to maintain a pro-autophagy gene program that poises HSCs for rapid autophagy induction. However, how HSCs sense metabolic stress and activate autophagy is still unknown, and much remains to be understood about the role of autophagy in normal and transformed HSCs. We will use both pharmacological and genetic approaches to dissect the contribution of autophagy to HSC biology, and our established Scl- tTA:TRE-BCR/ABL (tTA-BA) mouse model of human chronic phase CML (Reynaud et al., 2011) to probe the function of autophagy in leukemia-initiating stem cell (LSC) activity and CML development. In Specific Aim 1, we will determine the mechanisms by which HSCs activate autophagy. We will use our established protocols to induce metabolic stress in HSCs ex vivo upon cytokine withdrawal and in vivo upon food deprivation, and will take advantage of existing genetic mouse models and chemical inhibitors to identify how HSCs sense metabolic stress and trigger autophagy induction. These approaches will establish how HSCs elicit a protective autophagy response upon metabolic challenges. In Specific Aim 2, we will address how loss of autophagy affects HSC function and genomic stability in vivo, and investigate whether alternative forms of protein and organelle turnover can support the long-term maintenance of autophagy-deficient HSCs. These approaches will delineate how autophagy is normally utilized by HSCs in vivo, and how its abrogation alters normal hematopoiesis. In Specific Aim 3, we will probe the function of autophagy in transformed BCR/ABL- expressing HSCs, and will take advantage of our inducible tTA-BA mouse model to investigate the contribution of autophagy to CML pathogenesis and response of CML LSCs to tyrosine kinase inhibitor (TKI) treatments. These approaches will provide important new insights into the mechanisms of malignant transformation in the blood system. They will elucidate the contribution of autophagy in HSC transformation and CML development, and determine how the autophagy machinery can be manipulated to achieve a therapeutic benefit. Taken together, these studies will uncover how corruption of an essential mechanism of cell preservation normally used by HSCs to maintain blood homeostasis contributes to the aberrant function of transformed HSCs and the development of blood diseases.